ArticleERJ open research2022

Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD.

Nora Drick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.